<h4>Introduction</h4>First-generation somatostatin receptor ligands (SRLs) mainly target SSTR2, whereas neuroendocrine tumors (NETs) often express multiple SSTR subtypes, frequently SSTR5. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.